Platinum versus non-platinum chemotherapy regimens for small cell lung cancer

Abstract

Platinum-based chemotherapy regimens did not offer a statistically significant benefit in survival or overall tumour response compared with non-platinum-based regimens. However, platinum-based chemotherapy regimens did increase complete response rates, at the cost of higher adverse events including nausea and vomiting, anaemia and thrombocytopenia toxicity. These data suggest non-platinum chemotherapy regimens have a more advantageous risk-benefit profile. This systematic review highlights the lack of quality of life data in trials involving chemotherapy treatment for SCLC. With poor long-term survival associated with both treatment groups, the issue of the quality of the survival period takes on even more significance. It would be beneficial for future trials in this area to include a quality of life assessment.

<p>Adherence to recommended clinical guidelines in extensive disease small-cell lung cancer across the US, Europe, and Japan</p>

“……”

<p>Adherence to recommended clinical guidelines in extensive disease small-cell lung cancer across the US, Europe, and Japan</p>

“……”

First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: clinical developments and future directions

“…Noteworthy, survival benefit is sustained with 22% of patients alive at 2 years which represents a substantial improvement compared with historical data. 52 …”

A Phase III Randomized Study Comparing a Chemotherapy with Cisplatin and Etoposide to a Etoposide Regimen without Cisplatin for Patients with Extensive Small-Cell Lung Cancer

“…The COCIS meta-analysis ( 21 ) of individual patient data, comparing carboplatin—or cisplatin—based chemotherapy, did not cover our present topic about the role of etoposide. More recently, a Cochrane meta-analysis ( 22 ) looked at the effect of platinum administration versus non-platinum combinations. No improvement in terms of 6, 12, and 24 months survival was noted.…”

<p>Adherence to recommended clinical guidelines in extensive disease small-cell lung cancer across the US, Europe, and Japan</p>

“……”

First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: clinical developments and future directions

“…Noteworthy, survival benefit is sustained with 22% of patients alive at 2 years which represents a substantial improvement compared with historical data. 52 …”

A Phase III Randomized Study Comparing a Chemotherapy with Cisplatin and Etoposide to a Etoposide Regimen without Cisplatin for Patients with Extensive Small-Cell Lung Cancer

“…The COCIS meta-analysis ( 21 ) of individual patient data, comparing carboplatin—or cisplatin—based chemotherapy, did not cover our present topic about the role of etoposide. More recently, a Cochrane meta-analysis ( 22 ) looked at the effect of platinum administration versus non-platinum combinations. No improvement in terms of 6, 12, and 24 months survival was noted.…”

<p>Adherence to recommended clinical guidelines in extensive disease small-cell lung cancer across the US, Europe, and Japan</p>

“……”

First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: clinical developments and future directions

“…Noteworthy, survival benefit is sustained with 22% of patients alive at 2 years which represents a substantial improvement compared with historical data. 52 …”

A Phase III Randomized Study Comparing a Chemotherapy with Cisplatin and Etoposide to a Etoposide Regimen without Cisplatin for Patients with Extensive Small-Cell Lung Cancer

“…The COCIS meta-analysis ( 21 ) of individual patient data, comparing carboplatin—or cisplatin—based chemotherapy, did not cover our present topic about the role of etoposide. More recently, a Cochrane meta-analysis ( 22 ) looked at the effect of platinum administration versus non-platinum combinations. No improvement in terms of 6, 12, and 24 months survival was noted.…”